Valeritas, a provider of drug delivery devices, has received the US Food and Drug Administration (FDA) clearance for its V-Go disposable insulin delivery device for the continuous subcutaneous delivery of insulin in preset basal rates and with on-demand bolus dosing for adult patients requiring insulin.
V-Go devices will be available in a preset basal rate to deliver 20, 30 or 40 Units of insulin in one 24-hour period (0.83 U/hr, 1.25U/hr or 1.67U/hr respectively) and on-demand bolus dosing in 2 Unit increments (up to 36 Units per one 24-hour time period).
Valeritas CEO Kristine Peterson said the V-Go disposable insulin delivery device is the first fully disposable, non-electronic basal-bolus device that is specifically designed with the Type 2 population in mind.
"We believe that the simple user features of the V-Go will allow more patients with diabetes to adhere to their insulin regimen, which ultimately may lead to better control," Peterson said.
The V-Go provides a continuous preset basal rate of insulin and allows for on-demand bolus dosing around mealtimes thereby providing an alternative to taking multiple daily insulin injections.
The V-Go is engineered to simplify basal-bolus insulin therapy for the millions of people suffering from Type 2 diabetes.
The V-Go is small, lightweight, and worn under the patients’ clothing and is not electronic while easy to operate and use.
The V-Go measures just 2.4 x 1.3 x 0.5 inches and weighs approximately 1 ounce when filled with insulin and patients apply a new V-Go to the skin daily for one 24-hour period. The V-Go, making it.